37142-39-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-BROMOETHOXY)BENZONITRILE is used as an intermediate in the synthesis of various pharmaceuticals for its potential applications in drug development.
Used in Organic Synthesis:
4-(2-BROMOETHOXY)BENZONITRILE is used as a building block in organic synthesis for the preparation of different types of compounds, including those with potential pharmaceutical applications.

InChI:InChI=1/C9H8BrNO/c10-5-6-12-9-3-1-8(7-11)2-4-9/h1-4H,5-6H2

Upstream product

• 34133-58-9 4-hydroxy-isophthalonitrile 
• 767-00-0 4-cyanophenol 
• 106-93-4 ethylene dibromide 
• 3328-57-2 sodium 4-cyanophenolate 

Downstream Products

• 46843-20-3 4-(2-(piperidin-1-yl)ethoxy)benzonitrile 
• 1134518-69-6 C₄₆H₅₁NO₂ 
• 855290-91-4 4-[2-(4-cyano-phenoxy)-ethylamino]-benzonitrile 
• 1323916-56-8 4-(2-(4-(thiophene-2-carbonyl)piperazin-1-yl)ethoxy)benzonitrile 
• 1352792-37-0 N-(thiazol-2-yl)-2-(4-(2-(4-cyanophenoxy)ethyl)piperazin-1-yl)acetamide 
• 940843-49-2 4-(2-(4-benzoylpiperazin-1-yl)ethoxy)benzonitrile 
• 351343-88-9 4-(2-(piperazin-1-yl)ethoxy)benzonitrile 
• 1448673-14-0 4-{2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)oxy]ethoxy}benzonitrile 
• 1448673-17-3 4-[2-(aminooxy)ethoxy]benzenecarboximidamide 
• 1448673-15-1 4-[2-(aminooxy)ethoxy]benzonitrile 
• 1448674-32-5 2-{4-[2-(aminooxy)ethoxy]phenyl}-4,5-dihydro-1H-imidazole 
• 1448674-31-4 tert-butyl {2-[4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]ethoxy}carbamate 
• 1448674-30-3 tert-butyl [2-(4-cyanophenoxy)ethoxy]carbamate 

Relevant academic research and scientific papers

Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens

Pentamidine, an FDA-approved antiparasitic drug, was recently identified as an outer membrane disrupting synergist that potentiates erythromycin, rifampicin, and novobiocin against Gram-negative bacteria. The same study also described a preliminary structure-activity relationship using commercially available pentamidine analogues. We here report the design, synthesis, and evaluation of a broader panel of bis-amidines inspired by pentamidine. The present study both validates the previously observed synergistic activity reported for pentamidine, while further assessing the capacity for structurally similar bis-amidines to also potentiate Gram-positive specific antibiotics against Gram-negative pathogens. Among the bis-amidines prepared, a number of them were found to exhibit synergistic activity greater than pentamidine. These synergists were shown to effectively potentiate the activity of Gram-positive specific antibiotics against multiple Gram-negative pathogens such as Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli, including polymyxin- and carbapenem-resistant strains.

DOPAMINE D2 RECEPTOR LIGANDS

The present invention relates to novel dopamine D2 receptor ligands. The invention further relates to functionally-biased dopamine D2 receptor ligands and the use of these compounds for treating or preventing central nervous system and systemic disorders associated with dysregulation of dopaminergic activity. The present invention relates to novel compounds that modulate dopamine D2 receptors. In particular, compounds of the present invention show functional selectivity at the dopamine D2 receptors and exhibit selectivity downstream of the D2 receptors, on the 0- arrestin pathway and/or on the cAMP pathway.

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.

New serotonin 5-HT1A receptor agonists endowed with antinociceptive activity in vivo

We report the synthesis of new compounds 4-35 based on two different openings (A and B) of the chromane ring present in the previously identified 5-HT1A receptor (5-HT1AR) ligand 3. The synthesized compounds were assessed for binding affinity, selectivity, and functional activity at the 5-HT1AR. Selected candidates resulting from B opening were also evaluated for their potential antinociceptive effect in vivo and pharmacokinetic properties in vitro. Analogue 19 [2-(4-{[2-(2-ethoxyphenoxy) ethyl]amino}butyl)tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione] has been characterized as a high-affinity and potent 5-HT1AR agonist (K i = 2.3 nM; EC50 = 19 nM). Pharmacokinetic studies indicated that compound 19 displays a good metabolic stability in human liver microsomes (t1/2 ～ 3 h and CLint = 3.5 mL/min/kg, at 5 μM), and a low level of protein binding (25%, at 5 μM). Interestingly, 19 (3 mg/kg, ip, and 30 mg/kg, po) caused significant attenuation of formalin-induced behavior in early and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was reversed by the selective 5-HT1AR antagonist WAY-100635. Thus, the new 5-HT1AR agonist identified in this work, 19, exhibits oral analgesic activity, and the results herein represent a step toward identifying new therapeutics for the control of pain.

AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS

The present invention relates to novel β-lactam compounds of formula (I), their preparation and use. In particular, this invention relates to novel β-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.

Getting Harder: Cobalt(III)-Template synthesis of catenanes and rotaxanes

The synthesis of catenanes and rotaxanes using the hard trivalent transition metal ion cobalt(III) bas a template is reported. Tridentate dianionic pyridine-2,6-dicarboxamido ligands, each with two terminal alkene groups, coordinate Co(III) in a mutually

PIPERIDINE AND PIPERAZINE DERIVATIVES

Compounds of general formula (I) in which R1, m, X, n, Y and R3 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.

PIPERIDINE AND PIPERAZINE DERIVATIVES

Compounds of general formula (Ia): in which R1, A1, m, X, n, Y and R3 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.

3,8-Diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias

There is provided compounds of formula (I), wherein R1, R2 and Ra to Rb have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and v

Oxabispidine compounds useful in the treatment of cardiac arrhyythmias

There is provided compounds of formula I, wherein R1, R2, R3, R4, R41to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.